Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5635)
•••
Comment by Noteableon Aug 20, 2024 2:31pm
51 Views
Post# 36188403

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancerAs part of the pro-inflammatory activity, certain signals, referred to as “damage-associated molecular patterns”, (DAMPs) are emitted. DAMPs are endogenous molecules that would have been concealed in normal cells but that are released upon stress, cell injury, or cell death. As a result of this signaling pattern, an interphase is established with the host immune system (particularly with dendritic cells). Following exposure of dendritic cells to cancer cells, they succumb to ‘immunogenic cell death’ (ICD). This leads to priming of the adaptive arm of the immune system (consisting of various T-cell subsets). These activated T cells in turn target therapy-resistant cancer cells. This underpins the theory that chemotherapeutic agents, oncolytic viruses and peptides may induce ICD and in a basic way explain ONCY's pelareorep is also able to remodel the TME and overcome T-cell resistance and T-cell exhaustion.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities